Core Viewpoint - A securities class action lawsuit has been filed against Applied Therapeutics, Inc. for alleged misconduct related to its drug candidate, govorestat, during the Class Period from January 3, 2024, to December 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who acquired Applied Therapeutics securities during the specified Class Period [1]. - The lead plaintiff deadline for the lawsuit is set for February 18, 2025 [1][3]. - The complaint alleges that the defendants made false or misleading statements and failed to disclose non-adherence to trial protocols and good clinical practices, which posed a significant risk of FDA rejection of trial data [2]. Group 2: Lead Plaintiff Process - Investors in Applied Therapeutics can seek to be appointed as lead plaintiff representatives by the deadline of February 18, 2025, or choose to remain absent class members [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or small group with the largest financial interest [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm encourages investors who have suffered significant losses to contact them for more information regarding the lawsuit [4].
APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit